
    
      The purpose of this study is to determine efficacy and safety of the biweekly scheme with
      Capecitabine and Irinotecan, plus bevacizumab in patients with metastatic colorectal cancer.

        -  Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks

        -  Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks

        -  Bevacizumab: 5 mg/kg day 1, every 2 Weeks
    
  